FGF2 and periodontitis: A clinical study was conducted to test the safety and efficacy of 0.3% basic fibroblast growth factor (REGROTH®, Kaken Pharmaceutical Co., Ltd., Tokyo, Japan) in combination with CO3Ap-granules in the treatment of severe alveolar bone defects as the result of moderate-to-severe periodontitis in 10 subjects.